Quantification of 18F-florbetapir PET: comparison of two analysis methods

Purpose 18 F-Florbetapir positron emission tomography (PET) can be used to image amyloid burden in the human brain. A previously developed research method has been shown to have a high test-retest reliability and good correlation between standardized uptake value ratio (SUVR) and amyloid burden at a...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of nuclear medicine and molecular imaging Vol. 42; no. 5; pp. 725 - 732
Main Authors Hutton, Chloe, Declerck, Jerome, Mintun, Mark A., Pontecorvo, Michael J., Devous, Michael D., Joshi, Abhinay D.
Format Journal Article
LanguageEnglish
Published Berlin/Heidelberg Springer Berlin Heidelberg 01.04.2015
Subjects
Online AccessGet full text
ISSN1619-7070
1619-7089
1619-7089
DOI10.1007/s00259-015-2988-7

Cover

Abstract Purpose 18 F-Florbetapir positron emission tomography (PET) can be used to image amyloid burden in the human brain. A previously developed research method has been shown to have a high test-retest reliability and good correlation between standardized uptake value ratio (SUVR) and amyloid burden at autopsy. The goal of this study was to determine how well SUVRs computed using the research method could be reproduced using an automatic quantification method, developed for clinical use. Methods Two methods for the quantitative analysis of 18 F-florbetapir PET were compared in a diverse clinical population of 604 subjects from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and in a group of 74 younger healthy controls (YHC). Cortex to cerebellum SUVRs were calculated using the research method, which is based on SPM, yielding ‘research SUVRs’, and using syngo.PET Amyloid Plaque, yielding ‘sPAP SUVRs’. Results Mean cortical SUVRs calculated using the two methods for the 678 subjects were correlated ( r  = 0.99). Linear regression of sPAP SUVRs on research SUVRs was used to convert the research method SUVR threshold for florbetapir positivity of 1.10 to a corresponding threshold of 1.12 for sPAP. Using the corresponding thresholds, categorization of SUVR values were in agreement between research and sPAP SUVRs for 96.3 % of the ADNI images. SUVRs for all YHC were below the corresponding thresholds. Conclusion Automatic florbetapir PET quantification using sPAP yielded cortex to cerebellum SUVRs which were correlated and in good agreement with the well-established research method. The research SUVR threshold for florbetapir positivity was reliably converted to a corresponding threshold for sPAP SUVRs.
AbstractList Purpose 18 F-Florbetapir positron emission tomography (PET) can be used to image amyloid burden in the human brain. A previously developed research method has been shown to have a high test-retest reliability and good correlation between standardized uptake value ratio (SUVR) and amyloid burden at autopsy. The goal of this study was to determine how well SUVRs computed using the research method could be reproduced using an automatic quantification method, developed for clinical use. Methods Two methods for the quantitative analysis of 18 F-florbetapir PET were compared in a diverse clinical population of 604 subjects from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and in a group of 74 younger healthy controls (YHC). Cortex to cerebellum SUVRs were calculated using the research method, which is based on SPM, yielding ‘research SUVRs’, and using syngo.PET Amyloid Plaque, yielding ‘sPAP SUVRs’. Results Mean cortical SUVRs calculated using the two methods for the 678 subjects were correlated ( r  = 0.99). Linear regression of sPAP SUVRs on research SUVRs was used to convert the research method SUVR threshold for florbetapir positivity of 1.10 to a corresponding threshold of 1.12 for sPAP. Using the corresponding thresholds, categorization of SUVR values were in agreement between research and sPAP SUVRs for 96.3 % of the ADNI images. SUVRs for all YHC were below the corresponding thresholds. Conclusion Automatic florbetapir PET quantification using sPAP yielded cortex to cerebellum SUVRs which were correlated and in good agreement with the well-established research method. The research SUVR threshold for florbetapir positivity was reliably converted to a corresponding threshold for sPAP SUVRs.
(18)F-Florbetapir positron emission tomography (PET) can be used to image amyloid burden in the human brain. A previously developed research method has been shown to have a high test-retest reliability and good correlation between standardized uptake value ratio (SUVR) and amyloid burden at autopsy. The goal of this study was to determine how well SUVRs computed using the research method could be reproduced using an automatic quantification method, developed for clinical use.PURPOSE(18)F-Florbetapir positron emission tomography (PET) can be used to image amyloid burden in the human brain. A previously developed research method has been shown to have a high test-retest reliability and good correlation between standardized uptake value ratio (SUVR) and amyloid burden at autopsy. The goal of this study was to determine how well SUVRs computed using the research method could be reproduced using an automatic quantification method, developed for clinical use.Two methods for the quantitative analysis of (18)F-florbetapir PET were compared in a diverse clinical population of 604 subjects from the Alzheimer's Disease Neuroimaging Initiative (ADNI) and in a group of 74 younger healthy controls (YHC). Cortex to cerebellum SUVRs were calculated using the research method, which is based on SPM, yielding 'research SUVRs', and using syngo.PET Amyloid Plaque, yielding 'sPAP SUVRs'.METHODSTwo methods for the quantitative analysis of (18)F-florbetapir PET were compared in a diverse clinical population of 604 subjects from the Alzheimer's Disease Neuroimaging Initiative (ADNI) and in a group of 74 younger healthy controls (YHC). Cortex to cerebellum SUVRs were calculated using the research method, which is based on SPM, yielding 'research SUVRs', and using syngo.PET Amyloid Plaque, yielding 'sPAP SUVRs'.Mean cortical SUVRs calculated using the two methods for the 678 subjects were correlated (r = 0.99). Linear regression of sPAP SUVRs on research SUVRs was used to convert the research method SUVR threshold for florbetapir positivity of 1.10 to a corresponding threshold of 1.12 for sPAP. Using the corresponding thresholds, categorization of SUVR values were in agreement between research and sPAP SUVRs for 96.3 % of the ADNI images. SUVRs for all YHC were below the corresponding thresholds.RESULTSMean cortical SUVRs calculated using the two methods for the 678 subjects were correlated (r = 0.99). Linear regression of sPAP SUVRs on research SUVRs was used to convert the research method SUVR threshold for florbetapir positivity of 1.10 to a corresponding threshold of 1.12 for sPAP. Using the corresponding thresholds, categorization of SUVR values were in agreement between research and sPAP SUVRs for 96.3 % of the ADNI images. SUVRs for all YHC were below the corresponding thresholds.Automatic florbetapir PET quantification using sPAP yielded cortex to cerebellum SUVRs which were correlated and in good agreement with the well-established research method. The research SUVR threshold for florbetapir positivity was reliably converted to a corresponding threshold for sPAP SUVRs.CONCLUSIONAutomatic florbetapir PET quantification using sPAP yielded cortex to cerebellum SUVRs which were correlated and in good agreement with the well-established research method. The research SUVR threshold for florbetapir positivity was reliably converted to a corresponding threshold for sPAP SUVRs.
(18)F-Florbetapir positron emission tomography (PET) can be used to image amyloid burden in the human brain. A previously developed research method has been shown to have a high test-retest reliability and good correlation between standardized uptake value ratio (SUVR) and amyloid burden at autopsy. The goal of this study was to determine how well SUVRs computed using the research method could be reproduced using an automatic quantification method, developed for clinical use. Two methods for the quantitative analysis of (18)F-florbetapir PET were compared in a diverse clinical population of 604 subjects from the Alzheimer's Disease Neuroimaging Initiative (ADNI) and in a group of 74 younger healthy controls (YHC). Cortex to cerebellum SUVRs were calculated using the research method, which is based on SPM, yielding 'research SUVRs', and using syngo.PET Amyloid Plaque, yielding 'sPAP SUVRs'. Mean cortical SUVRs calculated using the two methods for the 678 subjects were correlated (r = 0.99). Linear regression of sPAP SUVRs on research SUVRs was used to convert the research method SUVR threshold for florbetapir positivity of 1.10 to a corresponding threshold of 1.12 for sPAP. Using the corresponding thresholds, categorization of SUVR values were in agreement between research and sPAP SUVRs for 96.3 % of the ADNI images. SUVRs for all YHC were below the corresponding thresholds. Automatic florbetapir PET quantification using sPAP yielded cortex to cerebellum SUVRs which were correlated and in good agreement with the well-established research method. The research SUVR threshold for florbetapir positivity was reliably converted to a corresponding threshold for sPAP SUVRs.
Author Devous, Michael D.
Declerck, Jerome
Hutton, Chloe
Pontecorvo, Michael J.
Mintun, Mark A.
Joshi, Abhinay D.
Author_xml – sequence: 1
  givenname: Chloe
  surname: Hutton
  fullname: Hutton, Chloe
  email: chloe.hutton@siemens.com
  organization: Siemens Molecular Imaging
– sequence: 2
  givenname: Jerome
  surname: Declerck
  fullname: Declerck, Jerome
  organization: Siemens Molecular Imaging
– sequence: 3
  givenname: Mark A.
  surname: Mintun
  fullname: Mintun, Mark A.
  organization: Avid Radiopharmaceuticals a wholly owned subsidiary of Eli Lilly and Company
– sequence: 4
  givenname: Michael J.
  surname: Pontecorvo
  fullname: Pontecorvo, Michael J.
  organization: Avid Radiopharmaceuticals a wholly owned subsidiary of Eli Lilly and Company
– sequence: 5
  givenname: Michael D.
  surname: Devous
  fullname: Devous, Michael D.
  organization: Avid Radiopharmaceuticals a wholly owned subsidiary of Eli Lilly and Company
– sequence: 6
  givenname: Abhinay D.
  surname: Joshi
  fullname: Joshi, Abhinay D.
  organization: Avid Radiopharmaceuticals a wholly owned subsidiary of Eli Lilly and Company
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25652817$$D View this record in MEDLINE/PubMed
BookMark eNp9kE1PwyAYgImZcR_6A7yYHr2gQEsBb2bZdMkSNZlnQilVlrZUaGP27-3s3MHDTryH53nf8EzBqHa1AeAaozuMELsPCBEqIMIUEsE5ZGdgglMsIENcjI4zQ2MwDWGLEOaEiwswJjSlhGM2Aau3TtWtLaxWrXV15IoI8yUsSucz06rG-uh1sXmItKsa5W0YkPbbRapW5S7YEFWm_XR5uATnhSqDuTq8M_C-XGzmz3D98rSaP66hJpQyqHjKaCwKqgzPDSeM5VwrlMSG6kylLKGYUJUrlhqtCyTiOMNxLBjXGidCx_EM3A57G---OhNaWdmgTVmq2rguSJymvYBJwnv05oB2WWVy2XhbKb-Tf9_vATwA2rsQvCmOCEZyn1gOiWWfWO4Ty73D_jnatr_xWq9sedIkgxn6K_WH8XLrOt9nDCekH5mzjlo
CitedBy_id crossref_primary_10_1007_s00259_016_3601_4
crossref_primary_10_1016_j_nicl_2016_05_004
crossref_primary_10_1016_j_nicl_2018_07_013
crossref_primary_10_6009_jjrt_2017_JSRT_73_4_298
crossref_primary_10_1259_bjr_20181020
crossref_primary_10_1007_s40336_017_0257_4
crossref_primary_10_1007_s13139_022_00767_1
crossref_primary_10_1007_s00259_015_3300_6
crossref_primary_10_1371_journal_pone_0177924
crossref_primary_10_3233_JAD_190329
crossref_primary_10_2174_1874471013666200729155717
crossref_primary_10_1016_j_ejmp_2023_102604
crossref_primary_10_1053_j_semnuclmed_2015_03_008
crossref_primary_10_1002_alz_13567
crossref_primary_10_1016_j_jalz_2016_11_007
crossref_primary_10_2147_CIA_S404908
crossref_primary_10_1007_s00259_017_3644_1
crossref_primary_10_3390_app10072628
crossref_primary_10_6009_jjrt_2021_JSRT_77_1_32
crossref_primary_10_1007_s00259_017_3750_0
Cites_doi 10.2967/jnumed.111.090340
10.1126/science.1072994
10.1006/nimg.2001.0978
10.1016/j.neuroimage.2012.12.014
10.1016/S1474-4422(11)70077-1
10.2967/jnumed.112.109009
10.1002/ana.20009
10.1016/S1474-4422(08)70001-2
10.1002/ana.22068
10.1016/S1474-4422(12)70142-4
10.1007/s00259-013-2415-x
10.1001/archneurol.2011.150
10.1001/jama.2010.2008
10.2967/jnumed.109.069088
10.1016/j.media.2011.05.002
10.2967/jnumed.112.115006
10.2967/jnumed.112.114785
10.1007/s00259-011-1745-9
10.2967/jnumed.113.120618
10.1016/j.jalz.2014.07.003
10.1007/s00259-014-2753-3
10.1109/NSSMIC.1993.373602
10.2967/jnumed.110.076315
ContentType Journal Article
Copyright Springer-Verlag Berlin Heidelberg 2015
Copyright_xml – notice: Springer-Verlag Berlin Heidelberg 2015
CorporateAuthor for the Alzheimer’s Disease Neuroimaging Initiative
Alzheimer’s Disease Neuroimaging Initiative
CorporateAuthor_xml – name: for the Alzheimer’s Disease Neuroimaging Initiative
– name: Alzheimer’s Disease Neuroimaging Initiative
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1007/s00259-015-2988-7
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1619-7089
EndPage 732
ExternalDocumentID 25652817
10_1007_s00259_015_2988_7
Genre Research Support, U.S. Gov't, Non-P.H.S
Comparative Study
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: Canadian Institutes of Health Research
– fundername: NIA NIH HHS
  grantid: U01 AG024904
GroupedDBID ---
-5E
-5G
-BR
-Y2
-~C
.86
.GJ
.VR
04C
06C
06D
0R~
0VY
199
1N0
203
29G
29~
2JN
2JY
2KM
2LR
2P1
2VQ
2~H
30V
36B
3V.
4.4
406
40D
53G
5GY
5QI
5RE
5VS
67Z
6NX
78A
7RV
7X7
88E
8AO
8FE
8FG
8FH
8FI
8FJ
8UJ
95-
95.
95~
96X
AAAVM
AACDK
AAHNG
AAIAL
AAJBT
AANXM
AANZL
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAYQN
AAYTO
AAYZH
ABAKF
ABBBX
ABBXA
ABDBF
ABECU
ABFTV
ABHQN
ABIPD
ABJNI
ABJOX
ABKCH
ABLJU
ABMNI
ABMQK
ABNWP
ABPLI
ABQBU
ABQSL
ABSXP
ABTEG
ABTKH
ABTMW
ABULA
ABUWG
ABUWZ
ABWNU
ABXPI
ACAOD
ACBXY
ACDTI
ACGFS
ACHSB
ACHVE
ACIWK
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACPRK
ACUDM
ACUHS
ACZOJ
ADBBV
ADHIR
ADINQ
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEBTG
AEFIE
AEFQL
AEGAL
AEGNC
AEJRE
AEKMD
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AEVLU
AEXYK
AFBBN
AFEXP
AFFNX
AFJLC
AFKRA
AFLOW
AFQWF
AFRAH
AFWTZ
AGAYW
AGDGC
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGVAE
AGWIL
AHAVH
AHBYD
AHIZS
AHKAY
AHMBA
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AJZVZ
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AOCGG
ARAPS
ARMRJ
AXYYD
AZFZN
B-.
B0M
BA0
BBNVY
BDATZ
BENPR
BGLVJ
BGNMA
BHPHI
BKEYQ
BMSDO
BPHCQ
BSONS
BVXVI
CAG
CCPQU
COF
CSCUP
DDRTE
DL5
DNIVK
DPUIP
DU5
EAD
EAP
EAS
EBB
EBC
EBD
EBLON
EBO
EBS
EBX
EHN
EIHBH
EIOEI
EJD
EMB
EMK
EMOBN
EN4
EPL
EPT
ESBYG
ESX
EX3
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GNWQR
GQ6
GQ7
GQ8
GRRUI
GXS
H13
HCIFZ
HF~
HG5
HG6
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I09
IHE
IJ-
IKXTQ
IMOTQ
ITM
IWAJR
IXC
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
JBSCW
JCJTX
JZLTJ
KDC
KPH
LAS
LK8
LLZTM
M1P
M4Y
M7P
MA-
N2Q
N9A
NAPCQ
NB0
NDZJH
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OAM
OVD
P19
P62
P9S
PF0
PQQKQ
PROAC
PSQYO
PT4
PT5
Q2X
QOK
QOR
QOS
Q~Q
R89
R9I
RNI
RNS
ROL
RPX
RRX
RSV
RZK
S1Z
S26
S27
S28
S37
S3B
SAP
SCLPG
SDH
SISQX
SJYHP
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZ9
SZN
T13
T16
TEORI
TH9
TSG
TSK
TT1
TUS
U2A
U9L
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WK8
WOW
YLTOR
Z45
Z7R
Z7U
Z7W
Z7X
Z7Y
Z7Z
Z81
Z82
Z83
Z87
Z88
Z8M
Z8O
Z8Q
Z8R
Z8S
Z8T
Z8U
Z8V
Z8W
Z8Z
Z91
ZMTXR
~8M
AAPKM
AAYXX
ABBRH
ABDBE
ABFSG
ACSTC
ADHKG
AEZWR
AFDZB
AFHIU
AFOHR
AGQPQ
AHPBZ
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
ABRTQ
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PQGLB
7X8
PUEGO
ID FETCH-LOGICAL-c2557-a867539f5ae8de8277d8ca043e5cba6745125ada76eccf0933b133978cc149c33
ISSN 1619-7070
1619-7089
IngestDate Fri Sep 05 02:54:27 EDT 2025
Mon Jul 21 05:51:49 EDT 2025
Sun Jul 06 05:07:29 EDT 2025
Thu Apr 24 23:03:18 EDT 2025
Fri Feb 21 02:43:39 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords Amyloid
Florbetapir
Quantification
Alzheimer’s disease
PET
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c2557-a867539f5ae8de8277d8ca043e5cba6745125ada76eccf0933b133978cc149c33
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
PMID 25652817
PQID 1661331248
PQPubID 23479
PageCount 8
ParticipantIDs proquest_miscellaneous_1661331248
pubmed_primary_25652817
crossref_primary_10_1007_s00259_015_2988_7
crossref_citationtrail_10_1007_s00259_015_2988_7
springer_journals_10_1007_s00259_015_2988_7
PublicationCentury 2000
PublicationDate 20150400
PublicationDateYYYYMMDD 2015-04-01
PublicationDate_xml – month: 4
  year: 2015
  text: 20150400
PublicationDecade 2010
PublicationPlace Berlin/Heidelberg
PublicationPlace_xml – name: Berlin/Heidelberg
– name: Germany
PublicationTitle European journal of nuclear medicine and molecular imaging
PublicationTitleAbbrev Eur J Nucl Med Mol Imaging
PublicationTitleAlternate Eur J Nucl Med Mol Imaging
PublicationYear 2015
Publisher Springer Berlin Heidelberg
Publisher_xml – name: Springer Berlin Heidelberg
References Rowe, Villemagne (CR10) 2011; 52
Thomas, Erlandsson, Modat, Thurfjell, Vandenberghe, Ourselin (CR25) 2011; 38
Fleisher, Chen, Liu, Roontiva, Thiyyagura, Ayutyanont (CR13) 2011; 68
Hardy, Selkoe (CR1) 2002; 297
Clark, Schneider, Bedell, Beach, Bilker, Mintun (CR5) 2011; 305
Booij, Arbizu, Darcourt, Hesse, Nobili, Payoux (CR9) 2013; 40
CR18
Edison, Carter, Rinne, Gelosa, Herholz, Nordberg (CR22) 2013; 70
Joshi, Pontecorvo, Clark, Carpenter, Jennings, Sadowsky (CR15) 2012; 53
Rowe, Ackerman, Browne, Mulligan, Pike, O’Keefe (CR12) 2008; 7
Peyrat, Joshi, Mintun, Declerck (CR16) 2012
Wong, Rosenberg, Zhou, Kumar, Raymont, Ravert (CR19) 2010; 51
Barthel, Gertz, Dresel, Peters, Bartenstein, Buerger (CR4) 2011; 10
Landau, Breault, Joshi, Pontecorvo, Mathis, Jagust (CR6) 2013; 54
Lopresti, Klunk, Mathis, Hoge, Ziolko, Lu (CR11) 2005; 46
Vandenberghe, Van Laere, Ivanoiu, Salmon, Baslin, Triau (CR3) 2010; 68
Lundqvist, Lilja, Thomas, Lötjönen, Villemagne, Rowe (CR24) 2013; 54
Peyrat, Joshi, Mintun, Declerck (CR23) 2012
Roche, Ribes, Bach-Cuadra, Kruger (CR21) 2011; 15
Tzourio-Mazoyer, Landeau, Papathanassiou, Crivello, Etard, Delcroix (CR20) 2002; 15
CR27
CR26
Clark, Pontecorvo, Beach, Bedell, Coleman, Doraiswamy (CR14) 2012; 11
Friston, Ashburner, Kiebel, Nichols, Penny (CR17) 2007
Rowe, Pejoska, Mulligan, Jones, Chan, Svensson (CR7) 2013; 54
Klunk, Engler, Nordberg, Wang, Blomqvist, Holt (CR2) 2004; 55
Johnson, Minoshima, Bohnen, Donohoe, Foster, Herscovitch (CR8) 2013; 54
P Edison (2988_CR22) 2013; 70
AS Fleisher (2988_CR13) 2011; 68
J-M Peyrat (2988_CR16) 2012
2988_CR18
CM Clark (2988_CR14) 2012; 11
N Tzourio-Mazoyer (2988_CR20) 2002; 15
CC Rowe (2988_CR12) 2008; 7
DF Wong (2988_CR19) 2010; 51
R Lundqvist (2988_CR24) 2013; 54
J Hardy (2988_CR1) 2002; 297
BJ Lopresti (2988_CR11) 2005; 46
R Vandenberghe (2988_CR3) 2010; 68
KA Johnson (2988_CR8) 2013; 54
BA Thomas (2988_CR25) 2011; 38
H Barthel (2988_CR4) 2011; 10
CC Rowe (2988_CR7) 2013; 54
J-M Peyrat (2988_CR23) 2012
2988_CR27
2988_CR26
WE Klunk (2988_CR2) 2004; 55
SM Landau (2988_CR6) 2013; 54
(2988_CR17) 2007
A Roche (2988_CR21) 2011; 15
CC Rowe (2988_CR10) 2011; 52
AD Joshi (2988_CR15) 2012; 53
J Booij (2988_CR9) 2013; 40
CM Clark (2988_CR5) 2011; 305
21621449 - Med Image Anal. 2011 Dec;15(6):830-9
22749065 - Lancet Neurol. 2012 Aug;11(8):669-78
14991808 - Ann Neurol. 2004 Mar;55(3):306-19
23575995 - J Nucl Med. 2013 Jun;54(6):880-6
23359661 - J Nucl Med. 2013 Mar;54(3):476-90
21917849 - J Nucl Med. 2011 Nov;52(11):1733-40
21336694 - Eur J Nucl Med Mol Imaging. 2011 Jun;38(6):1104-19
20687209 - Ann Neurol. 2010 Sep;68(3):319-29
12130773 - Science. 2002 Jul 19;297(5580):353-6
23619939 - Eur J Nucl Med Mol Imaging. 2013 Jul;40(7):1122-5
22331215 - J Nucl Med. 2012 Mar;53(3):378-84
23740104 - J Nucl Med. 2013 Aug;54(8):1472-8
21747008 - Arch Neurol. 2011 Nov;68(11):1404-11
16330558 - J Nucl Med. 2005 Dec;46(12 ):1959-72
25443857 - Alzheimers Dement. 2015 Jan;11(1):1-15.e1-4
23166389 - J Nucl Med. 2013 Jan;54(1):70-7
23261639 - Neuroimage. 2013 Apr 15;70:423-33
11771995 - Neuroimage. 2002 Jan;15(1):273-89
24647577 - Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1398-407
20501908 - J Nucl Med. 2010 Jun;51(6):913-20
18191617 - Lancet Neurol. 2008 Feb;7(2):129-35
21245183 - JAMA. 2011 Jan 19;305(3):275-83
21481640 - Lancet Neurol. 2011 May;10 (5):424-35
References_xml – volume: 53
  start-page: 378
  issue: 3
  year: 2012
  end-page: 384
  ident: CR15
  article-title: Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer’s disease and cognitively normal subjects
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.111.090340
– ident: CR18
– volume: 297
  start-page: 353
  issue: 5580
  year: 2002
  end-page: 356
  ident: CR1
  article-title: The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics
  publication-title: Science
  doi: 10.1126/science.1072994
– year: 2012
  ident: CR16
  publication-title: An automatic method for the quantification of uptake with florbetapir imaging
– volume: 15
  start-page: 273
  issue: 1
  year: 2002
  end-page: 289
  ident: CR20
  article-title: Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain
  publication-title: Neuroimage
  doi: 10.1006/nimg.2001.0978
– volume: 70
  start-page: 423
  year: 2013
  end-page: 433
  ident: CR22
  article-title: Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET
  publication-title: Neuroimage
  doi: 10.1016/j.neuroimage.2012.12.014
– volume: 10
  start-page: 424
  issue: 5
  year: 2011
  end-page: 435
  ident: CR4
  article-title: Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: a multicentre phase 2 diagnostic study
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(11)70077-1
– volume: 54
  start-page: 70
  issue: 1
  year: 2013
  end-page: 77
  ident: CR6
  article-title: Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.112.109009
– volume: 52
  start-page: 1733
  issue: 11
  year: 2011
  end-page: 1740
  ident: CR10
  article-title: Brain amyloid imaging
  publication-title: J Nucl Med
– volume: 55
  start-page: 306
  issue: 3
  year: 2004
  end-page: 319
  ident: CR2
  article-title: Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B
  publication-title: Ann Neurol
  doi: 10.1002/ana.20009
– volume: 7
  start-page: 129
  issue: 2
  year: 2008
  end-page: 135
  ident: CR12
  article-title: Imaging of amyloid beta in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(08)70001-2
– year: 2012
  ident: CR23
  publication-title: Influence of reconstruction methods and parameters in quantification of uptake with florbetapir imaging
– ident: CR27
– volume: 68
  start-page: 319
  issue: 3
  year: 2010
  end-page: 329
  ident: CR3
  article-title: 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial
  publication-title: Ann Neurol
  doi: 10.1002/ana.22068
– volume: 11
  start-page: 669
  issue: 8
  year: 2012
  end-page: 678
  ident: CR14
  article-title: Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(12)70142-4
– volume: 46
  start-page: 1959
  issue: 12
  year: 2005
  end-page: 1972
  ident: CR11
  article-title: Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: a comparative analysis
  publication-title: J Nucl Med
– year: 2007
  ident: CR17
  publication-title: Statistical parametric mapping: the analysis of functional brain images
– volume: 40
  start-page: 1122
  issue: 7
  year: 2013
  end-page: 1125
  ident: CR9
  article-title: Appropriate use criteria for amyloid PET imaging cannot replace guidelines: on behalf of the European Association of Nuclear Medicine
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-013-2415-x
– volume: 68
  start-page: 1404
  issue: 11
  year: 2011
  end-page: 1411
  ident: CR13
  article-title: Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease
  publication-title: Arch Neurol
  doi: 10.1001/archneurol.2011.150
– volume: 305
  start-page: 275
  issue: 3
  year: 2011
  end-page: 283
  ident: CR5
  article-title: Use of florbetapir-PET for imaging beta-amyloid pathology
  publication-title: JAMA
  doi: 10.1001/jama.2010.2008
– volume: 51
  start-page: 913
  issue: 6
  year: 2010
  end-page: 920
  ident: CR19
  article-title: In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18)
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.109.069088
– volume: 15
  start-page: 830
  issue: 6
  year: 2011
  end-page: 839
  ident: CR21
  article-title: On the convergence of EM-like algorithms for image segmentation using Markov random fields
  publication-title: Med Image Anal
  doi: 10.1016/j.media.2011.05.002
– volume: 54
  start-page: 1472
  issue: 8
  year: 2013
  end-page: 1478
  ident: CR24
  article-title: Implementation and validation of an adaptive template registration method for 18F-flutemetamol imaging data
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.112.115006
– ident: CR26
– volume: 54
  start-page: 880
  issue: 6
  year: 2013
  end-page: 886
  ident: CR7
  article-title: Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β-amyloid imaging in aging and dementia
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.112.114785
– volume: 38
  start-page: 1104
  issue: 6
  year: 2011
  end-page: 1119
  ident: CR25
  article-title: The importance of appropriate partial volume correction for PET quantification in Alzheimer’s disease
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-011-1745-9
– volume: 54
  start-page: 476
  issue: 3
  year: 2013
  end-page: 490
  ident: CR8
  article-title: Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.113.120618
– volume: 68
  start-page: 1404
  issue: 11
  year: 2011
  ident: 2988_CR13
  publication-title: Arch Neurol
  doi: 10.1001/archneurol.2011.150
– ident: 2988_CR27
  doi: 10.1016/j.jalz.2014.07.003
– volume: 46
  start-page: 1959
  issue: 12
  year: 2005
  ident: 2988_CR11
  publication-title: J Nucl Med
– volume-title: Influence of reconstruction methods and parameters in quantification of uptake with florbetapir imaging
  year: 2012
  ident: 2988_CR23
– volume: 305
  start-page: 275
  issue: 3
  year: 2011
  ident: 2988_CR5
  publication-title: JAMA
  doi: 10.1001/jama.2010.2008
– volume: 70
  start-page: 423
  year: 2013
  ident: 2988_CR22
  publication-title: Neuroimage
  doi: 10.1016/j.neuroimage.2012.12.014
– volume: 54
  start-page: 70
  issue: 1
  year: 2013
  ident: 2988_CR6
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.112.109009
– volume: 54
  start-page: 1472
  issue: 8
  year: 2013
  ident: 2988_CR24
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.112.115006
– volume: 11
  start-page: 669
  issue: 8
  year: 2012
  ident: 2988_CR14
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(12)70142-4
– ident: 2988_CR26
  doi: 10.1007/s00259-014-2753-3
– volume-title: Statistical parametric mapping: the analysis of functional brain images
  year: 2007
  ident: 2988_CR17
– volume: 68
  start-page: 319
  issue: 3
  year: 2010
  ident: 2988_CR3
  publication-title: Ann Neurol
  doi: 10.1002/ana.22068
– volume: 51
  start-page: 913
  issue: 6
  year: 2010
  ident: 2988_CR19
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.109.069088
– volume: 55
  start-page: 306
  issue: 3
  year: 2004
  ident: 2988_CR2
  publication-title: Ann Neurol
  doi: 10.1002/ana.20009
– volume: 53
  start-page: 378
  issue: 3
  year: 2012
  ident: 2988_CR15
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.111.090340
– volume-title: An automatic method for the quantification of uptake with florbetapir imaging
  year: 2012
  ident: 2988_CR16
– volume: 54
  start-page: 880
  issue: 6
  year: 2013
  ident: 2988_CR7
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.112.114785
– volume: 7
  start-page: 129
  issue: 2
  year: 2008
  ident: 2988_CR12
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(08)70001-2
– ident: 2988_CR18
  doi: 10.1109/NSSMIC.1993.373602
– volume: 15
  start-page: 273
  issue: 1
  year: 2002
  ident: 2988_CR20
  publication-title: Neuroimage
  doi: 10.1006/nimg.2001.0978
– volume: 40
  start-page: 1122
  issue: 7
  year: 2013
  ident: 2988_CR9
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-013-2415-x
– volume: 38
  start-page: 1104
  issue: 6
  year: 2011
  ident: 2988_CR25
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-011-1745-9
– volume: 10
  start-page: 424
  issue: 5
  year: 2011
  ident: 2988_CR4
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(11)70077-1
– volume: 297
  start-page: 353
  issue: 5580
  year: 2002
  ident: 2988_CR1
  publication-title: Science
  doi: 10.1126/science.1072994
– volume: 54
  start-page: 476
  issue: 3
  year: 2013
  ident: 2988_CR8
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.113.120618
– volume: 52
  start-page: 1733
  issue: 11
  year: 2011
  ident: 2988_CR10
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.110.076315
– volume: 15
  start-page: 830
  issue: 6
  year: 2011
  ident: 2988_CR21
  publication-title: Med Image Anal
  doi: 10.1016/j.media.2011.05.002
– reference: 16330558 - J Nucl Med. 2005 Dec;46(12 ):1959-72
– reference: 23359661 - J Nucl Med. 2013 Mar;54(3):476-90
– reference: 11771995 - Neuroimage. 2002 Jan;15(1):273-89
– reference: 22331215 - J Nucl Med. 2012 Mar;53(3):378-84
– reference: 23166389 - J Nucl Med. 2013 Jan;54(1):70-7
– reference: 20687209 - Ann Neurol. 2010 Sep;68(3):319-29
– reference: 14991808 - Ann Neurol. 2004 Mar;55(3):306-19
– reference: 12130773 - Science. 2002 Jul 19;297(5580):353-6
– reference: 22749065 - Lancet Neurol. 2012 Aug;11(8):669-78
– reference: 23740104 - J Nucl Med. 2013 Aug;54(8):1472-8
– reference: 23619939 - Eur J Nucl Med Mol Imaging. 2013 Jul;40(7):1122-5
– reference: 23575995 - J Nucl Med. 2013 Jun;54(6):880-6
– reference: 25443857 - Alzheimers Dement. 2015 Jan;11(1):1-15.e1-4
– reference: 21245183 - JAMA. 2011 Jan 19;305(3):275-83
– reference: 21481640 - Lancet Neurol. 2011 May;10 (5):424-35
– reference: 21917849 - J Nucl Med. 2011 Nov;52(11):1733-40
– reference: 21747008 - Arch Neurol. 2011 Nov;68(11):1404-11
– reference: 21336694 - Eur J Nucl Med Mol Imaging. 2011 Jun;38(6):1104-19
– reference: 18191617 - Lancet Neurol. 2008 Feb;7(2):129-35
– reference: 20501908 - J Nucl Med. 2010 Jun;51(6):913-20
– reference: 21621449 - Med Image Anal. 2011 Dec;15(6):830-9
– reference: 23261639 - Neuroimage. 2013 Apr 15;70:423-33
– reference: 24647577 - Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1398-407
SSID ssj0018289
Score 2.1077766
Snippet Purpose 18 F-Florbetapir positron emission tomography (PET) can be used to image amyloid burden in the human brain. A previously developed research method has...
(18)F-Florbetapir positron emission tomography (PET) can be used to image amyloid burden in the human brain. A previously developed research method has been...
SourceID proquest
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 725
SubjectTerms Adolescent
Adult
Aged
Algorithms
Alzheimer Disease - diagnostic imaging
Aniline Compounds
Brain - diagnostic imaging
Cardiology
Case-Control Studies
Data Interpretation, Statistical
Ethylene Glycols
Female
Humans
Imaging
Male
Medicine
Medicine & Public Health
Middle Aged
Nuclear Medicine
Oncology
Original Article
Orthopedics
Positron-Emission Tomography - methods
Radiology
Radiopharmaceuticals
Title Quantification of 18F-florbetapir PET: comparison of two analysis methods
URI https://link.springer.com/article/10.1007/s00259-015-2988-7
https://www.ncbi.nlm.nih.gov/pubmed/25652817
https://www.proquest.com/docview/1661331248
Volume 42
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZpC2MvY_dll-LBnmZUfJMl722XZF1ps2w4kDcjyzIUWrskzgb79TuyJNtZ2tHtRRhjS-acT8fn6NwQekN5HhNBSixYGWDQ_3PMpSdxxIMiVOGMfq7OIc9m8fEiOlmS5Wi0GWaXNPmR-HVtXsn_cBXuAV9Vluw_cLabFG7ANfAXRuAwjLfi8bcN17E-nd7nsykuwQTPZcOvzlfufJIqm18Muw26zc_a5bYYiW4hvb7xhN5oq5Wqe8xXnS--dTpc2t667vll2-2oB0nTWHf-Rd1h55OESVZaAJ_IrlBCm5II_77KJg_1B6xzVTwLDOQf9SDG37iyzFmFTwYhLlq8grmGqaebBh3Ja-4ZmRwFA-yRgYClOk16R_DrWA_VY4uo-C-CgwTAQvu_nPXsz75m08XpaZZOlukeOggoVd79gw-T2fx7535SZqiy1O2nWXe411af3V5iW6HZsVJ2POyt4pLeR_eMxeG81_B5gEayeojunBk-PkJftlHk1KXzB4ocQNE7p8eQegQw5FgMOQZDj9FiOkk_HmPTYAMLsCQp5gzMxTApCZeskAxoUTDBvSiUROQ8phFog4QXnMaw0Ut19pX7ISiwTAgwrEUYPkH7VV3JZ8iJS0mSUhBOaRnlBWeh9GIv4YTShIFaPUaepVImTPV51QTlIuvqZreEzYCwmSJsRsfobffKlS698reHX1vSZyAgldeLV7LerDMfNFAQOUHExuip5kk3HXwYCZgPb7uWSZnZWuub13p-i7VeoLv9BniJ9pvVRr4C9bXJD9EeXVIY2fTzoQHeb8y8mcQ
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Quantification+of+18F-florbetapir+PET%3A+comparison+of+two+analysis+methods&rft.jtitle=European+journal+of+nuclear+medicine+and+molecular+imaging&rft.au=Hutton%2C+Chloe&rft.au=Declerck%2C+Jerome&rft.au=Mintun%2C+Mark+A&rft.au=Pontecorvo%2C+Michael+J&rft.date=2015-04-01&rft.issn=1619-7089&rft.eissn=1619-7089&rft.volume=42&rft.issue=5&rft.spage=725&rft_id=info:doi/10.1007%2Fs00259-015-2988-7&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1619-7070&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1619-7070&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1619-7070&client=summon